INSIGHTS •   •   •   •   •   •   •   •   •   •   •  

Author: Ken Kahtava Created: 9/13/2012 2:34 PM RssIcon
Insights on innovation in rare disease translational science and research.
By Ken Kahtava on 3/27/2013 8:29 AM
We applaud Pfizer's Chief Medical Officer for sounding the call for innovation in drug development. Could not agree with her more that patient engagement in the earliest stages will drive better data and outcomes, and that all stakeholders need to consider creative partnering to break down the barriers.
By Ken Kahtava on 3/13/2013 11:01 AM
Excellent compendium from our friends at FasterCures of the people, organizations and partnerships being developed to accelerate treatments to patients with unmet medical needs.
By Ken Kahtava on 1/18/2013 12:03 PM
30 years after the Orphan Drug Act of 1983, we've come a long way, and while the road ahead looks promising, it's anything but smooth.
By Ken Kahtava on 12/10/2012 3:05 PM
In summarizing his take on the recent Partnering for Cures conference in NY, Pfizer's head of R&D, Mikael Dolsten proclaims that even the world's largest pharmaceutical company can not, and should not, go it alone.
By Ken Kahtava on 9/13/2012 3:22 PM
Majority of rare disease patients turn to patient advocacy groups as singular source of clinical trial information.